News - Clinical Trial disruptions due to Covid-19

With November quickly approaching, it is safe to say that the global Covid-19 pandemic has influenced the entire world for the main part of 2020. With over 500 companies publicly announcing clinical trial disruptions, the clinical research industry has been hit fairly hard since early March 2020. Hereby, many companies have delayed the initiation of planned trials or withdrawn them completely, while others have paused enrollments in their active trials or have terminated the trial completely.


As the majority of clinical trials are still relying on in-person visits of patients and potential study candidates, disruption is based on patient safety measures, strict lockdown requirements, social distancing rules, as well as the high demand for medical professionals to help treat Covid-19 patients. After the first extreme peak of Covid-19 was slowly declining, many research sites started to resume their activities, including patient recruitment and enrollments. With the number of cases is globally increasing again in Europe and the United States, clinical trials need to strategize how to continue their trials without losing more time and money.


The United States shows the highest number of resumed clinical trials


According to the GlobalData’s Pharma Intelligence Center, the number of resumed clinical trials has actually increased, from 741 to 808 resumed trials, 82.4% of those trials are currently actively recruiting potential study candidates. 7.3% of resumed trials have already concluded patient recruitment and 0.5% of trials are awaiting recruitment of study participants. Those numbers suggest a slight increase in clinical trials, even though the number of recruiting and completed trials has slowed down since September.


Until now, the United States has shown to be the country with most resuming clinical trials (70.7%), followed by the UK (8.6%), and France (7.4%). Depending on when the second wave of the coronavirus will decline again, the clinical trial activity might increase again, even though at a much slower rate than originally planned.


Partner with accredited companies


Since 2015, our team has been hard at work raising awareness of clinical trials across the globe. A Forbes ‘30 Under 30’ company and a graduate of the renowned Techstar program in New York, Citruslabs is at the forefront of patient recruitment and retention technologies. With over 3 million patients now recorded on our databases, our patient recruitment dashboard is fast becoming the most efficient method of trial recruitment.

Now a #1 health app in 17 countries, our Mindmate app is helping to revolutionize the way we think about healthcare. Mindmate “[takes] senior care into the digital age” (Forbes, 2018) by providing people with the cognitive decline the essential tools to help them rebuild and maintain strong mental health. Trusted by millions of users, our health community continues to grow as the content available expands to the needs of individuals today.

With more than 200 research sites now using the Citrus platform to screen thousands of patients every month, researchers are now well on their way to finding new treatments for hundreds of different health conditions - something that just would not be possible without a technological solution. Make sure that your clinical trial is in the lucky 12% and turn that luck into guaranteed results with Citrus.

  • Interested in finding out more? Get in touch with us here, and check out our archives for all our top tips and tricks on running successful clinical trials in today's constantly changing industry.

Still a little unsure? Check out what our customers have to say about us here.


Citruslabs

Copyright © 2020

All rights reserved

MindMate Inc.

Company

Product

Support

  • LinkedIn
  • Twitter
  • Instagram

1639 11th Street, Suite B-208, Santa Monica, CA 90404